Late-breaking clinical trials announced for New York Valves 2025
The Cardiovascular Research Foundation (CRF) has announced the late-breaking clinical trials for New York Valves 2025. The three-day event, now in its second year, is scheduled for June 25-27 in New York City.
New York Valves has replaced the Transcatheter Valve Therapy conference CRF hosted for many years. It focuses all aspects of care for structural heart disease, with a heavy emphasis on interventional treatments and advanced imaging.
The late-breaking clinical trials at New York Valves 2025 have been divided by the valve at the heart of the research. The focus of the first day is the aortic valve, for example, while day 2 is focused on the tricuspid valve and day 3 is focused on the mitral valve.
“This dynamic meeting brings together interventional cardiologists, cardiac surgeons, clinical cardiologists, cardiac imagers, heart failure specialists, and other members of the heart team in the spirit of multidisciplinary collaboration,” according to CRF. “Attendees will have the unique opportunity to leverage the collective expertise of diverse specialties to create innovative and personalized treatment strategies for patients with valvular and structural heart disease.”
Wednesday, June 25, 2025
Late-Breaking Clinical Trials 1: Aortic | 10:30 a.m. - 11:30 a.m.
Guideline Directed Indications and Consequences of Delayed AVR in Patients With Asymptomatic, Severe Aortic Stenosis:
Results From the EARLY TAVR Trial. Presenter: Allan Schwartz, MD
Electronic Provider Notification Mitigates Sex Disparities in the Treatment of Severe Aortic Stenosis: Insights From the DETECT AS Trial.
Presenter: Sammy Elmariah, MD
TAVR Reintervention Strategies: Unveiling Trends and Outcomes of Redo TAVR and TAVR Explant.
Presenter: Shinichi Fukuhara, MD
Early U.S. Commercial Experience With a Self-Expandable Transcatheter Aortic Valve With Intra-Annular Leaflet Position.
Presenter: Santiago Garcia, MD
Thursday, June 26, 2025
Late Breaking Clinical Trials 2: Tricuspid | 10:30 a.m. - 11:30 a.m.
Clinical Progression in TRILUMINATE Pivotal Control Group: Insights Into Crossover to Tricuspid TEER
Presenter: Matthew J. Price, MD
TRISCEND II: Echocardiographic Outcomes One Year Post Transcatheter Tricuspid Valve Replacement
Presenter: Paul A. Grayburn, MD
Defining an Optimal Result of Transcatheter Tricuspid Valve Intervention: Results From the Tri-QOL Study
Presenter: Suzanne V. Arnold, MD
Prognostic Impact of Extra-Tricuspid Valve Involvement After Tricuspid Transcatheter Edge-to-Edge Repair: Insights from the Bronx Valve and TRISPA Registries
Presenter: Julio Echarte Morales, MD
Friday, June 27, 2025
Late Breaking Clinical Trials 3: Mitral | 10:30 a.m. — 11:30 a.m.
Two-Year Outcomes Following Transfemoral Transseptal Transcatheter Mitral Valve Replacement: Intrepid TMVR Early Feasibility Study
Presenter: Gilbert H. L. Tang, MD, MBA
Clinical and Quality-of-Life Outcomes With the PASCAL System in Early Commercial Experience From the STS/ACC TVT Registry
Presenter: Santiago Garcia, MD
Global and Regional Burden of Non-Rheumatic Degenerative Mitral Valve Disease: Implications for Transcatheter Therapies
Guido Ascione, MD
One Year Results of a Clinical Study Using a Novel Polymeric Valve for Surgical Mitral Valve Replacement
Presenter: Isaac George, MD
New York Valves 2025 is also scheduled to include more than 20 live cases, 14 featured clinical science presentations and more than 150 moderated abstracts. In addition, a one-day LAAC Summit will also take place on June 26.
Michael has more than 19 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.